Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptors, Antigen, B-Cel”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Ended earlyNCT05972720
What this trial is testing

Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
CancerRelapsed/Refractory Large B-cell Lymphoma (LBCL)
CARGO Therapeutics 101
Testing effectiveness (Phase 2)Looking for participantsNCT06479356
What this trial is testing

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 12
Large-scale testing (Phase 3)Ended earlyNCT05664217
What this trial is testing

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphoma
Nektar Therapeutics 15
Testing effectiveness (Phase 2)Looking for participantsNCT06718244
What this trial is testing

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Who this might be right for
Acute Lymphoblastic Leukemia
Ruijin Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06777264
What this trial is testing

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

Who this might be right for
Acute Lymphoblastic LeukemiaB Cell ALL
First Affiliated Hospital of Zhejiang University 20
Not applicableActive Not RecruitingNCT07777120
What this trial is testing

Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma

Who this might be right for
Marginal Zone Lymphoma
Bristol-Myers Squibb 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT05393804
What this trial is testing

Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 24
Early research (Phase 1)Looking for participantsNCT06626919
What this trial is testing

Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Who this might be right for
Muscular DiseasesNeuromuscular ManifestationsAutoimmune+4 more
Arcellx, Inc. 30
Not applicableNot Yet RecruitingNCT07346820
What this trial is testing

VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation

Who this might be right for
Stem Cell Transplantation, HematopoieticV(D)J RecombinationReceptors, Antigen, B-Cel
Umeå University 65
Testing effectiveness (Phase 2)Study completedNCT03483103
What this trial is testing

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, NonhodgkinLymphoma, B-Cell+1 more
Juno Therapeutics, a Subsidiary of Celgene 74
Testing effectiveness (Phase 2)Study completedNCT03744676
What this trial is testing

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Who this might be right for
Lymphoma, Non-HodgkinLymphomaLymphoma, B-Cell+7 more
Juno Therapeutics, a Subsidiary of Celgene 104
Not applicableNot Yet RecruitingNCT07577583
What this trial is testing

Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel

Who this might be right for
B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc. 32
Testing effectiveness (Phase 2)UnknownNCT06149169
What this trial is testing

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Who this might be right for
Lymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 10